RCUS
Price
$29.97
Change
-$0.29 (-0.96%)
Updated
Jul 9, 04:59 PM (EDT)
Capitalization
3.81B
34 days until earnings call
Intraday BUY SELL Signals
SLN
Price
$9.78
Change
-$0.17 (-1.71%)
Updated
Jul 9, 04:59 PM (EDT)
Capitalization
212.56M
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RCUS vs SLN

RCUS vs SLN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RCUS vs. SLN commentary
Jul 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a Buy and SLN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2026
Stock price -- (RCUS: $30.26 vs. SLN: $10.15)
Brand notoriety: RCUS and SLN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCUS: 87% vs. SLN: 92%
Market capitalization -- RCUS: $3.81B vs. SLN: $212.56M
RCUS [@Biotechnology] is valued at $3.81B. SLN’s [@Biotechnology] market capitalization is $212.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $126.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCUS’s FA Score shows that 0 FA rating(s) are green whileSLN’s FA Score has 0 green FA rating(s).

  • RCUS’s FA Score: 0 green, 5 red.
  • SLN’s FA Score: 0 green, 5 red.
According to our system of comparison, both RCUS and SLN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCUS’s TA Score shows that 5 TA indicator(s) are bullish while SLN’s TA Score has 6 bullish TA indicator(s).

  • RCUS’s TA Score: 5 bullish, 5 bearish.
  • SLN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SLN is a better buy in the short-term than RCUS.

Price Growth

RCUS (@Biotechnology) experienced а +4.63% price change this week, while SLN (@Biotechnology) price change was -3.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.57%. For the same industry, the average monthly price growth was +15.43%, and the average quarterly price growth was +1817.75%.

Reported Earning Dates

RCUS is expected to report earnings on Aug 12, 2026.

SLN is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+3.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($3.81B) has a higher market cap than SLN($213M). SLN YTD gains are higher at: 66.941 vs. RCUS (26.983). SLN has higher annual earnings (EBITDA): -76.56M vs. RCUS (-350M). RCUS has more cash in the bank: 822M vs. SLN (70.1M). SLN has less debt than RCUS: SLN (136K) vs RCUS (113M). RCUS has higher revenues than SLN: RCUS (236M) vs SLN (839K).
RCUSSLNRCUS / SLN
Capitalization3.81B213M1,787%
EBITDA-350M-76.56M457%
Gain YTD26.98366.94140%
P/E RatioN/AN/A-
Revenue236M839K28,129%
Total Cash822M70.1M1,173%
Total Debt113M136K83,088%
FUNDAMENTALS RATINGS
RCUS vs SLN: Fundamental Ratings
RCUS
SLN
OUTLOOK RATING
1..100
4345
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
3535
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
5035

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLN's Valuation (68) in the null industry is in the same range as RCUS (70) in the Pharmaceuticals Major industry. This means that SLN’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's Profit vs Risk Rating (90) in the Pharmaceuticals Major industry is in the same range as SLN (100) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.

RCUS's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as SLN (99) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.

RCUS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as SLN (35) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as SLN (100) in the null industry. This means that RCUS’s stock grew similarly to SLN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCUSSLN
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 14 days ago
87%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
RCUS
Daily Signal:
Gain/Loss:
SLN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CXSE38.06N/A
N/A
WisdomTree China ex-State-Owd Entpr ETF
MATE29.80N/A
N/A
Man Active Trend Enhanced ETF
ARMH127.07-0.22
-0.17%
ARM HOLDINGS PLC ADRHEDGED
SCHK35.96-0.13
-0.36%
Schwab 1000 ETF
BRZU88.34-1.11
-1.24%
Direxion Daily MSCI Brazil Bull 2X ETF

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+0.03%
XNCR - RCUS
52%
Loosely correlated
N/A
VIR - RCUS
50%
Loosely correlated
N/A
DYN - RCUS
46%
Loosely correlated
N/A
NRIX - RCUS
45%
Loosely correlated
N/A
AURA - RCUS
44%
Loosely correlated
N/A
More

SLN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLN has been loosely correlated with CLLS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SLN jumps, then CLLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLN
1D Price
Change %
SLN100%
N/A
CLLS - SLN
43%
Loosely correlated
N/A
RCUS - SLN
39%
Loosely correlated
+0.03%
BEAM - SLN
38%
Loosely correlated
N/A
VIR - SLN
35%
Loosely correlated
N/A
EDIT - SLN
35%
Loosely correlated
N/A
More